AbbVie Inc. $ABBV Stock Holdings Lifted by Avanza Fonder AB

Avanza Fonder AB raised its position in shares of AbbVie Inc. (NYSE:ABBV) by 60.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,215 shares of the company’s stock after purchasing an additional 3,834 shares during the period. Avanza Fonder AB’s holdings in AbbVie were worth $2,334,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in ABBV. Vanguard Group Inc. increased its holdings in AbbVie by 0.3% in the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after buying an additional 448,554 shares during the last quarter. Norges Bank acquired a new stake in AbbVie in the second quarter valued at approximately $4,288,200,000. Legal & General Group Plc grew its position in AbbVie by 4.3% in the third quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock worth $2,779,426,000 after acquiring an additional 493,420 shares in the last quarter. Wellington Management Group LLP grew its position in AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after acquiring an additional 8,646,424 shares in the last quarter. Finally, Amundi increased its stake in shares of AbbVie by 15.6% during the 3rd quarter. Amundi now owns 10,508,317 shares of the company’s stock worth $2,418,909,000 after purchasing an additional 1,414,621 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase‑1 obesity data for ABBV‑295: AbbVie reported dose‑dependent, meaningful weight loss from ABBV‑295 (a long‑acting amylin analog), marking the company’s formal entry into the anti‑obesity market and diversifying revenue beyond immunology and oncology — a potentially material long‑term growth driver if later‑stage trials succeed. AbbVie’s ABBV-295 Obesity Data Opens New Non Incretin Opportunity
• Positive Sentiment: Multi‑year MLB partnership expands “Striking Out Cancer” nationally: AbbVie was named the Official Pharmaceutical Partner of Major League Baseball, amplifying its cancer‑support initiative, broadening brand reach and CSR impact (each MLB strikeout triggers donations to Stand Up To Cancer). This raises AbbVie’s consumer visibility and may help patient‑facing positioning. AbbVie Named Official Pharmaceutical Partner of Major League Baseball (PR Newswire) MLB: AbbVie named official pharmaceutical partner
• Positive Sentiment: Recent fundamentals and legal risk reduction support the story: AbbVie beat top‑line estimates in its latest quarter, raised FY‑2026 guidance, and a Bloomberg Law report shows the company prevailed in a worker’s suit over family‑medical‑history queries — reducing a potential legal overhang. These items support earnings visibility and dividend stability. AbbVie to sponsor leading US baseball league AbbVie beats worker’s suit (Bloomberg Law)
• Neutral Sentiment: Positive media/analyst commentary on valuation: Several outlets (The Motley Fool, Kalkine) highlight AbbVie’s dividend, revenue growth and argue the stock looks attractively valued, which may support longer‑term investor interest but is not an immediate catalyst. Why AbbVie Stock Looks Like a Dirt Cheap Buy Right Now AbbVie Shares Rise on Revenue Growth (Kalkine)
• Negative Sentiment: Valuation and technical/financial quirks may limit near‑term upside: AbbVie trades below its 50‑ and 200‑day moving averages and shows a high reported P/E (~86.8) and a negative ROE figure (accounting effect), factors that can pressure sentiment and constrain multiple expansion until growth visibility improves. MarketBeat ABBV snapshot

Analyst Ratings Changes

ABBV has been the topic of a number of recent research reports. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Citigroup lowered their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and boosted their price target for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Finally, Piper Sandler upped their price target on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $253.15.

AbbVie Trading Down 0.0%

NYSE ABBV opened at $204.86 on Wednesday. The company has a fifty day simple moving average of $222.48 and a 200 day simple moving average of $224.74. The company has a market cap of $362.23 billion, a P/E ratio of 86.81, a P/E/G ratio of 0.71 and a beta of 0.34. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.4%. AbbVie’s payout ratio is presently 293.22%.

Insider Activity

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.08% of the stock is currently owned by insiders.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.